全文获取类型
收费全文 | 193篇 |
免费 | 18篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 4篇 |
基础医学 | 11篇 |
口腔科学 | 5篇 |
临床医学 | 9篇 |
内科学 | 85篇 |
皮肤病学 | 7篇 |
神经病学 | 13篇 |
特种医学 | 2篇 |
外科学 | 18篇 |
预防医学 | 21篇 |
肿瘤学 | 35篇 |
出版年
2021年 | 6篇 |
2020年 | 2篇 |
2019年 | 5篇 |
2018年 | 2篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 5篇 |
2014年 | 5篇 |
2013年 | 6篇 |
2012年 | 10篇 |
2011年 | 11篇 |
2010年 | 3篇 |
2009年 | 5篇 |
2008年 | 11篇 |
2007年 | 15篇 |
2006年 | 16篇 |
2005年 | 17篇 |
2004年 | 18篇 |
2003年 | 15篇 |
2002年 | 17篇 |
2001年 | 5篇 |
2000年 | 8篇 |
1999年 | 1篇 |
1998年 | 3篇 |
1997年 | 4篇 |
1996年 | 4篇 |
1994年 | 2篇 |
1991年 | 4篇 |
1990年 | 2篇 |
1989年 | 3篇 |
排序方式: 共有211条查询结果,搜索用时 15 毫秒
1.
2.
A Cayuela Domínguez 《Gaceta sanitaria / S.E.S.P.A.S》1989,3(13):467-471
In order to assess whether the exclusion of the province of Madrid from the Spanish areas having a high risk of cancer mortality from most locations (1975-1978)--as opposed to what has been observed in other provinces with similar characteristics--has remained in subsequent years, mortality due to malignant tumors in Madrid in 1980-1984 has been studied. Standardized Mortality Ratios (SMR) yielded values less than 100, which were statistically significant for most locations. The magnitude of the SMR observed under the heading "malignant tumor of unspecified location" must be noted, both in men (206,34) and women (189,61). The evolution of this heading as a percentage of total cancer deaths shows that Madrid has values considerably over the national mean, also in men (11,87%) and women (14,83%). The aspects related to the filling of death certificates that could explain a possible distortion of the pattern of cancer mortality in Madrid are discussed. 相似文献
3.
BACKGROUND: The aim of this paper is to analyse breast cancer mortality in Andalucia (Spain) between 1975 and 1999 based on age-period-cohort. PATIENTS AND METHODS: Mortality data were obtained from the Mortality Registry of Andalucia. Deaths and population were divided into 13 age groups and five 5-year periods. From this, age-specific mortality rates for 17 birth cohorts were computed. These were plotted and fitted to Poisson regression models to assess age, period and cohort effects. RESULTS: The best fit was found for the complete model, which simultaneously considered the effects of age-period-cohort. Cohort effects were found to be more important than period effects in terms of model fit. CONCLUSION: These effects were manifest as a seemingly consistent increase in the relative risk of breast cancer mortality with a three-fold increase in women born in the 1950s relative to those born in the 1890s. 相似文献
4.
Ramirez P Chavez R Majado M Munitiz V Muñoz A Hernandez Q Palenciano C Pino-Chavez G Loba M Minguela A Yelamos J Vizcaino AS Asensi H Cayuela MG Segura B Marin F Rubio A Rios A Fuente T Robles R Sanchez F Sansano T Acosta F Rodriguez JM Navarro F Cabezuelo J 《Transplantation proceedings》2000,32(5):1112-1113
5.
6.
7.
Impact of TCR status and genotype on outcome in adult T-cell acute lymphoblastic leukemia: a LALA-94 study 总被引:2,自引:0,他引:2
Asnafi V Buzyn A Thomas X Huguet F Vey N Boiron JM Reman O Cayuela JM Lheritier V Vernant JP Fiere D Macintyre E Dombret H 《Blood》2005,105(8):3072-3078
Patients with T-cell acute lymphoblastic leukemias (T-ALLs) within the Leucemies Aigues Lymphoblastiques de l'Adulte-94 (LALA-94) prospective trial were treated with a 4-drug per 4-week induction, with intermediate-dose cytarabine and mitoxantrone salvage treatment for patients not achieving complete remission (CR) in 1 course. Only the latter received allografts, if possible, thus providing an informative setting for assessing early response. Representative patients with T-ALL (91 patients) were classified into surface T-cell receptor (TCR)-expressing T-ALL patients (TCRalphabeta+ or TCRgammadelta+), pre-alphabeta T-ALL patients (cTCRbeta+, TCR-), and immature (IM) cTCRbeta-, TCR- T-ALL patients; 81 patients underwent genotyping for SIL-TAL1, CALM-AF10, HOX11, and HOX11L2. Overall, CR was obtained in 81 (89%) patients; relapse rate was 62% at 4 years and overall survival (OS) rate was 38%. CR rate was significantly lower in IM T-ALL patients after 1 course (45% vs 87%; P < .001) and after salvage (74% vs 97%; P = .002), with the latter inducing a higher rate of CR (9 [64%] of 14) than initial induction. Once CR was obtained, cumulative relapse rates were similar for IM, pre-alphabeta, and TCR+ T-ALL patients (P = .51), but were higher in HOX11L2 (83%) and SIL-TAL1 (82%) T-ALL patients compared with other genetic subgroups (48%; P = .05). This was associated with an inferior OS for HOX11L2 T-ALLs (13% vs 47% in HOX11L2-T-ALLs; P = .009). The majority of patients with HOX11 T-ALL underwent allografting, predominantly in second CR, but were not associated with a superior OS. Both TCR and genotypic stratification can therefore contribute to risk-adapted management of adult T-ALLs. 相似文献
8.
Julien Rohmer Amélie Couteau-Chardon Julie Trichereau Kewin Panel Cyrielle Gesquiere Raouf Ben Abdelali Audrey Bidet Jean-Sébastien Bladé Jean-Michel Cayuela Pascale Cony-Makhoul Vincent Cottin Eric Delabesse Mikaël Ebbo Olivier Fain Pascale Flandrin Lionel Galicier Catherine Godon Nathalie Grardel Aurélien Guffroy Mohamed Hamidou Mathilde Hunault Etienne Lengline Faustine Lhomme Ludovic Lhermitte Irène Machelart Laurent Mauvieux Catherine Mohr Marie-Joelle Mozicconacci Dina Naguib Franck E. Nicolini Jerome Rey Philippe Rousselot Suzanne Tavitian Louis Terriou Guillaume Lefèvre Claude Preudhomme Jean-Emmanuel Kahn Matthieu Groh CEREO GBMHM collaborators 《American journal of hematology》2020,95(11):1314-1323
FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia (F/P+ MN-eo) is a rare disease: robust epidemiological data are lacking and reported issues are scarce, of low sample-size and limited follow-up. Imatinib mesylate (IM) is highly efficient but no predictive factor of relapse after discontinuation has yet been identified. One hundred and fifty-one patients with F/P+ MN-eo (143 males; mean age at diagnosis 49 years; mean annual incidence: 0.18 case per million population) were included in this retrospective nationwide study involving all French laboratories who perform the search of F/P fusion gene (study period: 2003-2019). The main organs involved included the spleen (44%), skin (32%), lungs (30%), heart (19%) and central nervous system (9%). Serum vitamin B12 and tryptase levels were elevated in 74/79 (94%) and 45/57 (79%) patients, respectively, and none of the 31 patients initially treated with corticosteroids achieved complete hematologic remission. All 148 (98%) IM-treated patients achieved complete hematologic and molecular (when tested, n = 84) responses. Forty-six patients eventually discontinued IM, among whom 20 (57%) relapsed. In multivariate analysis, time to IM initiation (continuous HR: 1,01 [0.99-1,03]; P = .05) and duration of IM treatment (continuous HR: 0,97 [0,95-0,99]; P = .004) were independent factors of relapse after discontinuation of IM. After a mean follow-up of 80 (56) months, the 1, 5- and 10-year overall survival rates in IM-treated patients were 99%, 95% and 84% respectively. In F/P+ MN-eo, prompt initiation of IM and longer treatment durations may prevent relapses after discontinuation of IM. 相似文献
9.